Here's how the Journal of Life Sciences introduces it's current web-edition cover story on FDA reform:
The FDA needs to rethink the way it communicates in an age of empowered patients.
MUCH HAS CHANGED over the past 25 years, but one of the immutables has been that FDA tries to communicate important health messages without the resources or attitude necessary to do it well on a consistent basis, according to Peter J. Pitts, president of the Center for Medicine in the Public Interest. A big part of the problem is that not only have communications tools changed, but so have people and society. He says the FDA needs to change as well.
Here's the rest of the story:
http://www.tjols.com/index.jsp
And the good news is that Commissioner von Eschenbach believes in strident and robust constituency outreach.
The FDA needs to rethink the way it communicates in an age of empowered patients.
MUCH HAS CHANGED over the past 25 years, but one of the immutables has been that FDA tries to communicate important health messages without the resources or attitude necessary to do it well on a consistent basis, according to Peter J. Pitts, president of the Center for Medicine in the Public Interest. A big part of the problem is that not only have communications tools changed, but so have people and society. He says the FDA needs to change as well.
Here's the rest of the story:
http://www.tjols.com/index.jsp
And the good news is that Commissioner von Eschenbach believes in strident and robust constituency outreach.
